Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 1.0-40.0,  Recurrent Cutaneous Melanoma Recurrent Lip and Oral Cavity Carcinoma Recurrent Malignant Endocrine Neoplasm Recurrent Malignant Female Reproductive System Neoplasm Recurrent Malignant Male Reproductive System Neoplasm Recurrent Malignant Mesothelioma Recurrent Malignant Neoplasm of Multiple Primary Sites Recurrent Malignant Oral Neoplasm Recurrent Malignant Pharyngeal Neoplasm Recurrent Malignant Skin Neoplasm Recurrent Malignant Soft Tissue Neoplasm Recurrent Malignant Solid Neoplasm Recurrent Malignant Thyroid Gland Neoplasm Recurrent Malignant Urinary System Neoplasm Refractory Cutaneous Melanoma Refractory Malignant Bone Neoplasm Refractory Malignant Endocrine Neoplasm Refractory Malignant Female Reproductive System Neoplasm Refractory Malignant Male Reproductive System Neoplasm Refractory Malignant Mesothelioma Refractory Malignant Neoplasm of Multiple Primary Sites Refractory Malignant Oral Neoplasm Refractory Malignant Pharyngeal Neoplasm Refractory Malignant Skin Neoplasm Refractory Malignant Soft Tissue Neoplasm Refractory Malignant Solid Neoplasm Refractory Malignant Thyroid Gland Neoplasm Refractory Malignant Urinary System Neoplasm Patients with relapsed or refractory solid tumors and without known curative therapy or therapy proven to proven to prolong survival with acceptable quality of life Patients older than 21 years must have a solid tumor considered by study doctor to be of the childhood cancer type Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age Documentation of measurable or evaluable non-measurable disease At least one documented histological verification of solid tumor diagnosis. Can be from original diagnosis or more recent Patient must have fully recovered (i.e. returned to baseline) from the clinically significant acute treatment-related toxicities of all prior treatments prior to beginning treatment on this protocol with exceptions of cytopenias resulting from persistent disease, hearing loss and alopecia Performance level as measured by Karnofsky >= 60% for patients > 16 years of age or Lansky >= 60% for patients =< 16 years of age Creatinine clearance >= 60 mL/min/1.73m^2 (calculated by 24 hour [h] urine collection or nuclear glomerular filtration rate [GFR] scan if 24 h collection is not possible) or a serum creatinine based on age and gender as follows Age, maximum serum creatinine (mg/dL) month to < 6 months, male 0.4, female 0.4  Primary tumors of the central nervous system Chronic corticosteroid dependence that is unable to be weaned to discontinue Determined by study doctor that patient is unlikely to meet after screening Uncontrolled arrhythmias or uncontrolled symptoms of cardiac disease noted by screening history and physical. Patients with known cardiac dysfunction should have an ejection fraction (EF) > 40% documented by echocardiogram (ECHO) Patients where the burden of pulmonary metastasis, location, or bulkiness of disease may cause high morbidity if localized swelling such as causing uncontrolled symptoms, oxygen dependence, or location near a major bronchi as determined by investigator Pregnant females Any uncontrolled systemic infection